To investigate the mechanism of valsartan protecting podocytes and inhibiting renal injury in diabetic rats. The rat model of diabetic nephropathy was induced by combination of valsartan and high-sugar and high-fat diet. The urinary protein content, renal index, inflammatory and antioxidant indexes in the kidney, renal pathological changes and podocyte holes were investigated. Membrane WT1 and P-Cadherin protein expression levels. Compared with the model group, the 24h urine protein content of valsartan was significantly decreased (P<0.05). Valsartan significantly inhibited the body weight of the model group (P<0.01), and significantly inhibited The increase of renal index (P<0.05); the high and middle doses of valsartan could significantly reduce the levels of IL-β, TNF-α and IL-6 in rat kidney (P<0.05-0.01). The valsartan high and middle dose groups significantly reduced MDA content in rat kidney (P<0.05), and significantly increased SOD activity (P<0.05). HE and PAS staining showed that valsartan was used in model group rats. The pathological changes were alleviated, and the glomerular morphology returned to normal. The protein expression of WT1 and P-Cadherin in the kidney of DN rats by Western blot showed that P- in the kidney tissue of valsartan rats. The expression levels of Cadherin and WT1 protein were significantly increased (P<0.05). Valsartan can regulate the expression of podocyte membrane proteins WT1 and P-Cadherin to protect podocytes, and then repair renal function and anti-diabetic nephropathy.
| Published in | American Journal of Life Sciences (Volume 6, Issue 3) |
| DOI | 10.11648/j.ajls.20180603.12 |
| Page(s) | 47-51 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Valsartan, Diabetic Nephropathy, Podocyte, P-Cadherin, WT1 Protein
| [1] | Wadie W, El-Tanbouly DM. Vinpocetine mitigates proteinuria and podocytes injury in a rat model of diabetic nephropathy. European journal of pharmacology. 2017; 814: 187-95. |
| [2] | Peng T, Chang X, Wang J, Zhen J, Yang X, Hu Z. Protective effects of tacrolimus on podocytes in early diabetic nephropathy in rats. Molecular medicine reports. 2017; 15 (5): 3172-8. |
| [3] | Mukhi D, Nishad R, Menon RK, Pasupulati AK. Novel Actions of Growth Hormone in Podocytes: Implications for Diabetic Nephropathy. Frontiers in medicine. 2017; 4: 102. |
| [4] | Liu Y, Zhang J, Wang Y, Zeng X. Apelin involved in progression of diabetic nephropathy by inhibiting autophagy in podocytes. Cell death & disease. 2017; 8 (8): e3006. |
| [5] | Huang SS, Ding DF, Chen S, Dong CL, Ye XL, Yuan YG, et al. Resveratrol protects podocytes against apoptosis via stimulation of autophagy in a mouse model of diabetic nephropathy. Scientific reports. 2017; 7: 45692. |
| [6] | Hsu YH, Li HH, Sung JM, Chen WY, Hou YC, Weng YH, et al. Interleukin-20 targets podocytes and is upregulated in experimental murine diabetic nephropathy. Experimental & molecular medicine. 2017; 49 (3): e310. |
| [7] | Guo Y, Song Z, Zhou M, Yang Y, Zhao Y, Liu B, et al. Infiltrating macrophages in diabetic nephropathy promote podocytes apoptosis via TNF-alpha-ROS-p38MAPK pathway. Oncotarget. 2017; 8 (32): 53276-87. |
| [8] | Zhang H, Luo W, Sun Y, Qiao Y, Zhang L, Zhao Z, et al. Wnt/beta-Catenin Signaling Mediated-UCH-L1 Expression in Podocytes of Diabetic Nephropathy. International journal of molecular sciences. 2016; 17 (9). |
| [9] | Tharaux PL, Huber TB. How Is Proteinuric Diabetic Nephropathy Caused by Disturbed Proteostasis and Autophagy in Podocytes? Diabetes. 2016; 65 (3): 539-41. |
| [10] | Sawada K, Toyoda M, Kaneyama N, Shiraiwa S, Moriya H, Miyatake H, et al. Upregulation of alpha3beta1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy. Journal of diabetes research. 2016; 2016: 9265074. |
| [11] | Liu F, Zong M, Wen X, Li X, Wang J, Wang Y, et al. Silencing of Histone Deacetylase 9 Expression in Podocytes Attenuates Kidney Injury in Diabetic Nephropathy. Scientific reports. 2016; 6: 33676. |
| [12] | Ji ZZ, Xu YC. Melatonin protects podocytes from angiotensin II-induced injury in an in vitro diabetic nephropathy model. Molecular medicine reports. 2016; 14 (1): 920-6. |
| [13] | He Y, Zhang M, Wu Y, Jiang H, Fu H, Cai Y, et al. Aberrant activation of Notch-1 signaling inhibits podocyte restoration after islet transplantation in a rat model of diabetic nephropathy. Cell death & disease. 2018; 9 (10): 950. |
| [14] | Zhang Y, Chen X, Yuan L, Wu J, Guo N, Liu J. Down-regulation of IRAK1 attenuates podocyte apoptosis in diabetic nephropathy through PI3K/Akt signaling pathway. Biochemical and biophysical research communications. 2018; 506 (3): 529-35. |
| [15] | Lei X, Zhang L, Li Z, Ren J. Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats. Drug design, development and therapy. 2018; 12: 2785-93. |
| [16] | Wang Y, Li H, Song SP. beta-Arrestin 1/2 Aggravates Podocyte Apoptosis of Diabetic Nephropathy via Wnt/beta-Catenin Pathway. Medical science monitor: international medical journal of experimental and clinical research. 2018; 24: 1724-32. |
| [17] | Pan Y, Jiang S, Hou Q, Qiu D, Shi J, Wang L, et al. Dissection of Glomerular Transcriptional Profile in Patients With Diabetic Nephropathy: SRGAP2a Protects Podocyte Structure and Function. Diabetes. 2018; 67 (4): 717-30. |
| [18] | Wang XB, Zhu H, Song W, Su JH. Gremlin Regulates Podocyte Apoptosis via Transforming Growth Factor-beta (TGF-beta) Pathway in Diabetic Nephropathy. Medical science monitor: international medical journal of experimental and clinical research. 2018; 24: 183-9. |
| [19] | Lv Z, Hu M, Fan M, Li X, Lin J, Zhen J, et al. Podocyte-specific Rac1 deficiency ameliorates podocyte damage and proteinuria in STZ-induced diabetic nephropathy in mice. Cell death & disease. 2018; 9 (3): 342. |
APA Style
Qingfen Wang, Rui Li, Weiwei Li, Lei Wang. (2018). Protective Effect of Valsartan on Podocyte Injury in Rats with Diabetic Nephropathy. American Journal of Life Sciences, 6(3), 47-51. https://doi.org/10.11648/j.ajls.20180603.12
ACS Style
Qingfen Wang; Rui Li; Weiwei Li; Lei Wang. Protective Effect of Valsartan on Podocyte Injury in Rats with Diabetic Nephropathy. Am. J. Life Sci. 2018, 6(3), 47-51. doi: 10.11648/j.ajls.20180603.12
AMA Style
Qingfen Wang, Rui Li, Weiwei Li, Lei Wang. Protective Effect of Valsartan on Podocyte Injury in Rats with Diabetic Nephropathy. Am J Life Sci. 2018;6(3):47-51. doi: 10.11648/j.ajls.20180603.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajls.20180603.12,
author = {Qingfen Wang and Rui Li and Weiwei Li and Lei Wang},
title = {Protective Effect of Valsartan on Podocyte Injury in Rats with Diabetic Nephropathy},
journal = {American Journal of Life Sciences},
volume = {6},
number = {3},
pages = {47-51},
doi = {10.11648/j.ajls.20180603.12},
url = {https://doi.org/10.11648/j.ajls.20180603.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajls.20180603.12},
abstract = {To investigate the mechanism of valsartan protecting podocytes and inhibiting renal injury in diabetic rats. The rat model of diabetic nephropathy was induced by combination of valsartan and high-sugar and high-fat diet. The urinary protein content, renal index, inflammatory and antioxidant indexes in the kidney, renal pathological changes and podocyte holes were investigated. Membrane WT1 and P-Cadherin protein expression levels. Compared with the model group, the 24h urine protein content of valsartan was significantly decreased (P<0.05). Valsartan significantly inhibited the body weight of the model group (P<0.01), and significantly inhibited The increase of renal index (P<0.05); the high and middle doses of valsartan could significantly reduce the levels of IL-β, TNF-α and IL-6 in rat kidney (P<0.05-0.01). The valsartan high and middle dose groups significantly reduced MDA content in rat kidney (P<0.05), and significantly increased SOD activity (P<0.05). HE and PAS staining showed that valsartan was used in model group rats. The pathological changes were alleviated, and the glomerular morphology returned to normal. The protein expression of WT1 and P-Cadherin in the kidney of DN rats by Western blot showed that P- in the kidney tissue of valsartan rats. The expression levels of Cadherin and WT1 protein were significantly increased (P<0.05). Valsartan can regulate the expression of podocyte membrane proteins WT1 and P-Cadherin to protect podocytes, and then repair renal function and anti-diabetic nephropathy.},
year = {2018}
}
TY - JOUR T1 - Protective Effect of Valsartan on Podocyte Injury in Rats with Diabetic Nephropathy AU - Qingfen Wang AU - Rui Li AU - Weiwei Li AU - Lei Wang Y1 - 2018/12/06 PY - 2018 N1 - https://doi.org/10.11648/j.ajls.20180603.12 DO - 10.11648/j.ajls.20180603.12 T2 - American Journal of Life Sciences JF - American Journal of Life Sciences JO - American Journal of Life Sciences SP - 47 EP - 51 PB - Science Publishing Group SN - 2328-5737 UR - https://doi.org/10.11648/j.ajls.20180603.12 AB - To investigate the mechanism of valsartan protecting podocytes and inhibiting renal injury in diabetic rats. The rat model of diabetic nephropathy was induced by combination of valsartan and high-sugar and high-fat diet. The urinary protein content, renal index, inflammatory and antioxidant indexes in the kidney, renal pathological changes and podocyte holes were investigated. Membrane WT1 and P-Cadherin protein expression levels. Compared with the model group, the 24h urine protein content of valsartan was significantly decreased (P<0.05). Valsartan significantly inhibited the body weight of the model group (P<0.01), and significantly inhibited The increase of renal index (P<0.05); the high and middle doses of valsartan could significantly reduce the levels of IL-β, TNF-α and IL-6 in rat kidney (P<0.05-0.01). The valsartan high and middle dose groups significantly reduced MDA content in rat kidney (P<0.05), and significantly increased SOD activity (P<0.05). HE and PAS staining showed that valsartan was used in model group rats. The pathological changes were alleviated, and the glomerular morphology returned to normal. The protein expression of WT1 and P-Cadherin in the kidney of DN rats by Western blot showed that P- in the kidney tissue of valsartan rats. The expression levels of Cadherin and WT1 protein were significantly increased (P<0.05). Valsartan can regulate the expression of podocyte membrane proteins WT1 and P-Cadherin to protect podocytes, and then repair renal function and anti-diabetic nephropathy. VL - 6 IS - 3 ER -
Information
Email: